Synergy CHC (SNYR) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 28, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Synergy CHC Corp.
Entity Central Index Key	1,562,733
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 18,900,000
Entity Common Stock, Shares Outstanding		81,692,954
Trading Symbol	SNYR
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 3,640,893	$ 338
Restricted cash	607,084
Accounts Receivable	3,979,857	$ 2,898
Note receivable from related party		16,077
Prepaid expenses	422,434	10,000
Inventory	686,655	26,064
Total Current Assets	9,336,923	$ 55,376
Fixed assets, net	12,017
Goodwill	11,496,402
Intangible assets, net	5,915,262
Debt issuance cost, net	378,852
Total Assets	27,139,456	$ 55,376
Current Liabilities:
Accounts payable and accrued liabilities	5,032,102	$ 74,642
Provision for income taxes payable	910,894
Earn out payment	2,551,500
Current portion of long-term debt, net of debt discount, related party	3,162,060	$ 100,000
Current portion of long-term debt	750,000	$ 6,400
Warrant derivative liability	3,096,179
Total Current Liabilities	15,502,735	$ 181,042
Long-term Liabilities:
Note payable	750,000
Royalty payable	258,897
Notes payable, net of debt discount, related parties	5,208,111
Total long-term liabilities	6,217,008
Total Liabilities	$ 21,719,743	$ 181,042
Commitments and contingencies
Stockholders’ Equity (Deficit):
Common stock, $0.00001 par value; 300,000,000 and 75,000,000 shares authorized, respectively; 81,692,954 and 62,100,000, shares issued and outstanding, respectively	$ 817	$ 621
Common stock to be issued	68,000	40,000
Additional paid in capital	13,920,735	867,004
Accumulated deficit	(8,569,841)	(1,033,291)
Total stockholders’ equity (deficit)	5,419,713	(125,666)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 27,139,456	$ 55,376

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	300,000,000	75,000,000
Common stock, shares issued	81,692,954	62,100,000
Common stock, shares outstanding	81,692,954	62,100,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 13,456,377	$ 9,158
Cost of Sales	5,308,130	5,616
Gross Profit	8,148,247	$ 3,542
Operating expenses
Selling and marketing	3,685,727
General and administrative	3,368,495	$ 961,636
Depreciation and amortization	608,002
Total operating expenses	7,662,224	$ 961,636
Income (loss) from operations	486,023	$ (958,094)
Other income (expenses)
Interest income	(1,460)
Interest expense	958,740
Remeasurement gain on translation of foreign subsidiary	(7,740)
Loss on change in fair value of derivative liability	1,028,921
Amortization of debt discount	5,499,640
Amortization of debt issuance cost	$ 154,525
Imputed and other interest expense		$ 1,998
Total other expenses	$ 7,632,626	1,998
Net loss before income taxes	(7,146,603)	$ (960,092)
Income tax expense	389,945
Net loss after tax	$ (7,536,548)	$ (960,092)
Net loss per share - basic and diluted	$ (0.11)	$ (0.01)
Weighted average common shares - basic and diluted	68,852,305	97,165,479

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock To Be Issued [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2013	$ 1,800	$ 58,578		$ (73,199)	$ (12,821)
Balance, shares at Dec. 31, 2013	180,000,000
Cancellation of Oro Corporation shares	$ (1,359)	1,359
Cancellation of Oro Corporation shares, shares	(135,900,000)
Common stock issued to Synergy shareholders	$ 160	24,840			$ 25,000
Common stock issued to Synergy shareholders, shares	16,000,000
Common stock issued for cash	$ 20	499,980			500,000
Common stock issued for cash, shares	2,000,000
Fair value of vested stock options		$ 282,247			282,247
Common stock to be issued for services			$ 40,000		$ 40,000
Common stock issued as part of the Contribution Agreement with Hand MD
Fair value of warrants issued to Breakthrough Products, Inc. as part of acquisition
Net loss				$ (960,092)	$ (960,092)
Balance at Dec. 31, 2014	$ 621	$ 867,004	$ 40,000	$ (1,033,291)	(125,666)
Balance, shares at Dec. 31, 2014	62,100,000
Common stock issued for cash	$ 1	$ 25,999			26,000
Common stock issued for cash, shares	40,000
Common stock to be issued for services			$ 28,000		28,000
Common stock issued as part of the Contribution Agreement with Hand MD	$ 21	$ 1,499,978			1,500,000
Common stock issued as part of the Contribution Agreement with Hand MD, shares	2,142,857
Common stock issued for acquisitions of Breakthrough Products, Inc.	$ 30	2,549,970			2,550,000
Common stock issued for acquisitions of Breakthrough Products, Inc., shares	3,000,000
Common stock issued for acquisitions of NomadChoice Pty Ltd.	$ 36	1,749,964			1,750,000
Common stock issued for acquisitions of NomadChoice Pty Ltd., shares	3,571,428
Common stock issued to settle accounts payable	$ 3	204,997			205,000
Common stock issued to settle accounts payable, shares	292,857
Common stock issued for conversion of notes payable	$ 4	99,996			100,000
Common stock issued for conversion of notes payable, shares	400,000
Common stock issued for exercise of warrants	$ 101	(99)			2
Common stock issued for exercise of warrants, shares	10,145,812
Fair value of warrants issued along with notes payable		5,968,801			5,968,801
Fair value of vested stock options		523,714			523,714
Fair value of warrants issued to Breakthrough Products, Inc. as part of acquisition		$ 430,411			430,411
Net loss				$ (7,536,548)	(7,536,548)
Balance at Dec. 31, 2015	$ 817	$ 13,920,735	$ 68,000	$ (8,569,839)	$ 5,419,713
Balance, shares at Dec. 31, 2015	81,692,954

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities
Net loss	$ (7,536,548)	$ (960,092)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt issuance cost	154,525
Depreciation and amortization	608,002
Stock based compensation expense	$ 551,714	$ 322,247
Loss on acquisition		$ 109,040
Amortization of debt discount	$ 5,499,640
Foreign currency transaction loss	54,600
Fair value of derivative loss	1,028,921
Remeasurement gain on translation of foreign subsidiary	(7,740)
Bad debts	50,000
Changes in operating assets and liabilities:
Accounts receivable	(1,317,050)	$ (2,898)
Inventory	(19,632)	(26,064)
Prepaid expense	(194,889)	10,000
Accounts payable and accrued liabilities	484,141	58,591
Net cash used in operating activities	(644,316)	$ (489,175)
Cash Flows from Investing Activities
Payments for acquisition of fixed assets	(7,833)
Restricted cash	(607,084)
Payments for acquisition of Focus Factor	(4,500,000)
Payments for acquisition transaction with Knight Therapeutics Inc.	(250,000)
Payments for acquisition of NomadChoice Pty Ltd	(2,918,200)
Cash acquired in acquisitions	3,883,261
Net cash used in investing activities	(4,399,856)
Cash Flows from Financing Activities
(Repayments to) advances from related party notes	16,077	$ (16,077)
Proceeds from notes payable	11,500,000	100,000
Repayment of notes payable	(1,150,000)	$ (97,640)
Payment of debt issuance cost	(533,377)
Dividends paid	(1,173,975)
Proceeds from exercise of warrants	2
Proceeds from issuance of common stock	26,000	$ 500,000
Net cash provided by financing activities	8,684,727	486,283
Net increase (decrease) in cash and cash equivalents	3,640,554	(2,892)
Cash and Cash Equivalents, beginning of period	338	3,230
Cash and Cash Equivalents, end of period	3,640,893	338
Supplemental Disclosure of Cash Flow Information:
Interest	806,740	$ 1,667
Income taxes	12,688
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Common stock issued for conversion of notes payable	100,000
Beneficial conversion feature on warrants issued concurrent with debt	5,968,801
Derivative liability at inception	2,067,258
Assumption of liabilities as part of asset purchase agreement with Factor Nutrition Labs, LLC	1,912,827
Assumption of liabilities as part of acquisition transaction with Knight Therapeutics Inc.	969,532
Note issued as part of asset purchase agreement with Factor Nutrition Labs, LLC	1,500,000
Common stock issued as part of contribution agreement with Hand MD	1,500,000
Common stock issued for the acquisition of Breakthrough Products, Inc.	2,550,000
Common stock issued for the acquisition of NomadChoice Pty Ltd.	1,750,000
Fair value of warrants issued as part of acquisition of Breakthrough Products, Inc.	430,411
Net liabilities taken over as part of acquisition of Breakthrough Products, Inc.	422,749
Net assets taken over as part of acquisition of NomadChoice Pty Ltd.	70,801
Common stock issued to settle payables	$ 205,000
Cancellation of common stock as part of purchase transaction		$ 1,359
Financing for prepaid insurance		20,000
Assumption of liabilities as part of acquisition transaction		84,040
Issuance of shares as part of acquisition transaction		$ 25,000

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Note 1 – Nature of the Business Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.” The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisition. Synergy is the sole owner of three subsidiaries: Neuragen Corp., Breakthrough Products, Inc. and NomadChoice Pty Ltd. and the results have been consolidated in these statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2015 and 2014 significant estimates included in these estimates are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, goodwill and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, stock based compensation, risk-free interest rate, and expected dividend rate. Cash and Cash Equivalents The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2015 the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2015, the uninsured balance amounted to $3,453,290. Capitalization of Fixed Assets The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred. Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. Accounts receivable Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. Advertising Expense The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying consolidated statements of operations. Research and Development Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred. Income Taxes The Company utilizes FASBASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made. Net Earnings (Loss) Per Common Share The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of December 31, 2015, options to purchase 5,000,000 shares of common stock and warrants to purchase 9,132,002 shares of common stock were outstanding these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Going Concern The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at December 31, 2015 of $8,569,841. The Company had a working capital deficit of $6,165,812 as of December 31, 2015. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. If the Company is unable to obtain adequate capital it could be forced to cease development of operations. In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Fair Value Measurements The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure. ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 - Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2015, the Company has determined that there were no assets or liabilities measured at fair value except for the warrant derivative liability which is valued using Level 3 estimates. Inventory Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items. Stock-Based Compensation The Company adopted the provisions of ASC 718. We estimate the fair value of stock options using a binomial model, consistent with the provisions of ASC 718 and SEC Staff Accounting Bulletin No. 107, Share-Based Payment. Option-pricing models require the input of highly subjective assumptions, including the price volatility of the underlying stock. We determined that the use of implied volatility is expected to be more reflective of market conditions and, therefore, could reasonably be expected to be a better indicator of our expected volatility than historical volatility. The expected term assumption used in calculating the estimated fair value of our stock-based compensation awards using the Black-Scholes-Merton (BSM) model is based on detailed historical data about employees’ exercise behavior, vesting schedules, and death and disability probabilities. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. We estimate the forfeiture rate based on historical experience of our stock-based awards that are granted, exercised and cancelled. We believe the resulting BSM calculation provides a more refined estimate of the fair value of our employee stock options. Long-lived Assets Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of December 31, 2015, our qualitative analysis of long-lived assets did not indicate any impairment. Goodwill An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of December 31, 2015 our qualitative analysis of goodwill did not indicate any impairment. Foreign Currency Translation The functional currency of each of the Company’s foreign subsidiaries is the U.S. Dollar. The Company’s subsidiary maintains its record using local currency (Australian Dollar). All monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at fiscal year-end exchange rates, non-monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary. Concentrations of Credit Risk In the normal course of business, the Company provided credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns. Warehousing costs Warehouse costs include all third party warehouse rent fees and any additional costs relating to assembly or special pack-outs of the Company products are charged to general and administrative expenses as incurred. Product display costs All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to general and administrative expenses as incurred. Warrant Derivative Liabilities ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. A Black-Scholes-Merton option-pricing model, with dilution effects, was utilized to estimate the fair value of the Warrant Derivative Liabilities as of November 12, 2015 and December 31, 2015. This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 Stock Price $ 0.46 $ 0.69 Exercise Price $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 Stock Volatility 157.56 % 152.07 % Risk-Free Rate 2.32 % 2.27 % Dividend Rate 0 % 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243 Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs. Debt Issuance Costs Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are capitalized and are being amortized to interest expense over the term of the related debt facilities. Impairment of Long-Lived Assets When facts and circumstances indicate that the carrying values of long-lived assets, including fixed assets, may be impaired, an evaluation of recoverability is performed by comparing the carrying value of the assets to projected future cash flows in addition to other quantitative and qualitative analyses. Upon indication that the carrying value of such assets may not be recoverable, the Company recognizes an impairment loss as a charge against current operations. Long-lived assets to be disposed of are reported at the lower of the carrying amount or fair value, less estimated costs to sell. The Company makes judgments related to the expected useful lives of long-lived assets and its ability to realize undiscounted cash flows in excess of the carrying amounts of such assets which are affected by factors such as the ongoing maintenance and improvements of the assets, changes in economic conditions and changes in operating performance. As the Company assesses the ongoing expected cash flows and carrying amounts of its long-lived assets, these factors could cause the Company to realize a material impairment charge. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses. Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The All transactions with related parties shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party. Segment Reporting Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. Recent Accounting Pronouncements ASU 2015-03 In April 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. The Company is evaluating the possible effect of this guidance on its financial statements. ASU 2015-02 In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows. ASU 2015-01 In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-17 In November 2014, the FASB issued ASU No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting.” This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows. ASU 2014-16 In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not currently have issued, nor are we investors in, hybrid financial instruments. Accordingly, we do not expect the adoption of ASU 2014-16 to have any effect on our financial position, results of operations or cash flows. ASU 2014-15 In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40)”. ASU 2014-15 provides guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-12 In June 2014, the FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not expect the adoption of ASU 2014-12 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-09 In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are still evaluating the effect of the adoption of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year for all entities and permits early adoption on a limited basis. ASU 2014-09 will be effective for the Company in the first quarter of 2018, and early adoption permitted in the first quarter of 2017. The Company does not believe the adoption of this ASU will have a material impact on its consolidated financial statements. ASU 2014-08 In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) and Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” ASU 2014-08 amends the definition for what types of asset disposals are to be considered discontinued operations, as well as amending the required disclosures for discontinued operations and assets held for sale. ASU 2014-08 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014. The adoption of ASU 2014-08 did not have any effect on our financial position, results of operations or cash flows. There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed financial position, results of operations or cash flows. Change in Fiscal Year End On April 21, 2014, the Company’s board of directors approved a change to the Company’s fiscal year end from July 31 to December 31 of each year.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Acquisitions	Note 3 – Acquisitions Asset Purchase Agreement with Factor Nutrition Labs, LLC: On January 22, 2015 (the “Closing Date”), the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Factor Nutrition Labs, LLC, a Delaware limited liability company (the “Seller”), Vita Partners, LLC, RPR Partners, LLC, and Thor Associates, Inc. (each a “Principal Owner”). Pursuant to the Purchase Agreement, the Company purchased all of the assets of the Seller’s line of business and products called FOCUS Factor (the product plus the business related to the product is collectively referred to as the “Focus Factor Business”) and assumed the accounts payable and contractual obligations of the Focus Factor Business for an aggregate purchase price of $6.0 million, with $4.5 million paid on the Closing Date, and $750,000 to be paid on or before January 20, 2016 and an additional $750,000 to be paid on or before January 20, 2017. Distribution Agreement On January 22, 2015, the Company and Knight entered into a Distribution, License and Supply Agreement (the “Distribution Agreement”), pursuant to which the Company granted to Knight an exclusive license to commercialize FOCUSFactor, FOCUSFactor Kids and Synergy Strip and all improvements thereto (together the “Licensed Products”) and appointed Knight as the exclusive distributor to offer to sell and sell the Licensed Products in Canada, and, at Knight’s election, one or more of Israel, Russia, and Sub-Saharan Africa. The Distribution Agreement provides that Knight may sublicense its rights or use sub-distributors under the Distribution Agreement on terms consistent with the terms of the Distribution Agreement. During the term of the Distribution Agreement, Knight agrees to obtain from the Company all its requirements for the Licensed Products and the Company agrees to supply the Licensed Products at its adjusted production cost plus a designated percentage and any applicable taxes. In the event of a long term inability by the Company to supply Knight with the Licensed Products, Knight is entitled to require, among other remedies, the Company to grant a Knight-designated third party a non-exclusive license to use all relevant intellectual property to manufacture and supply Knight with the Licensed Products for commercialization in the Territory. The term of the Distribution Agreement runs until 15 years from the date of the first commercial sale of a Licensed Product in Canada, and the Distribution Agreement will automatically renew for successive 15-year periods unless either party provides the other with written notice of its intention not to renew (a “Non-Renewal Notice”). The Company agrees that in the event it issues a Non-Renewal Notice, the Company will pay to Knight a non-renewal fee equal to the net sales of the Licensed Products achieved by Knight in the Territory during the eight calendar quarters preceding the date of such notice, plus all applicable taxes. Distribution Option Agreement In connection with the Loan Agreement, the Company entered into a Product Distribution Option Agreement, dated January 22, 2015 (the “Option Agreement”), pursuant to which the Company granted Knight the exclusive right to negotiate the exclusive distribution rights of any one or more of the Company’s products, including products from the Focus Factor Business, for the territories of Canada, Russia, Sub-Saharan Africa and Israel (the “Option”), pursuant to designated parameters. The Option Agreement is effective upon the date of the Option Agreement, will run until January 31, 2045, and will automatically renew thereafter for successive five-year periods unless either party provides a notice of termination prior to the Option Agreement’s expiration. If Knight does not exercise the option then the Company is free to contract for distribution with other parties, but only on terms no less favorable than those offered by Knight pursuant to the Option Agreement. On December 3, 2015, we entered into an Amendment to First Amendment Agreement (the “Second Amendment Agreement”) with Knight pursuant to which we agreed to grant distribution rights to Knight for Breakthrough’s products. To satisfy this obligation, on December 3, 2015, we also entered into an Amendment and Confirmation Agreement (the “Confirmation Agreement”) with Knight, Nomad and Breakthrough to amend the Distribution, License and Supply Agreement dated January 22, 2015 (the “Distribution Agreement”) between us and Knight to grant to Knight an exclusive license to commercialize any and all Nomad and Breakthrough products and appoint Knight as the exclusive distributor to offer and sell those products in Canada, Israel, Romania, Russia and each of the countries within Sub-Saharan Africa, which is the new “Territory” under the Distribution Agreement, as amended. Pursuant to the Second Amendment Agreement, Nomad will buy all Flat Tummy Tea products within the Territory for direct to consumer sales exclusively from Knight and/or its affiliates at cost of goods plus 60% of gross sales. The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on January 22, 2015. The Company expects the purchase price allocations for the acquisition of Focus Factor Business to be completed by the filing of first quarter 2016 statements. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts Receivable $ 2,733,167 Inventory 67,113 Intellectual Property 1,000,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 2,071,517 Liabilities Accounts Payable (971,381 ) Accrued Expenses (941,446 ) $ 6,000,000 The Customer relationships, the non-compete and the non-solicitation provisions will be amortized over their estimated useful lives of 5 years. During the year ended December 31, 2015, the Company charged to operations amortization expense of $384,720. The purchase price allocated to the acquisition of the assets of Factor Nutrition Labs, LLC is made up as follows: Amount Cash payment made on January 22, 2015 $ 4,500,000 Cash payment to be made on January 20, 2016 750,000 Cash payment to be made on January 20, 2017 750,000 Total $ 6,000,000 Pro forma Results of Operations. The historical operating results of the Focus Factor Business prior to its acquisition date have not been included in the Company’s historical consolidated operating results. Pro forma results of operations data (unaudited) for the years ended December 31, 2014 and 2013, as if the acquisition had occurred on January 1, 2013, are as follows: December 31, 2014 2013 Revenue $ 12,695,295 $ 10,629,171 Net (loss) income (183,471 ) 932,209 Pro forma revenue amount above does not include adjustment/reductions relating to certain discounts, coupons and placement fees and is presented gross. The amounts of revenue and net income of the FOCUS Factor Business since the acquisition date included in the consolidated statement of operations for the year ended December 31, 2015 are approximately $10,482,367 and $1,216,928, respectively. Asset Purchase Agreement with Knight Therapeutics Inc.: On June 26, 2015 (the “Closing Date”), Neuragen Corp., a Delaware corporation (“Neuragen”) and our wholly owned subsidiary, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Knight Therapeutics Inc., a Canadian corporation (“Knight Canada”). Pursuant to the Purchase Agreement, Neuragen purchased the U.S. rights related to an innovative OTC product that helps relieve pain caused by diabetic nerve damage (the “Purchased Assets”) for an aggregate purchase price of $1.2 million, with (i) $250,000 paid on the Closing Date, (ii) $250,000 to be paid on or before June 30, 2016, (iii) $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and (iv) 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million (collectively, “Total Consideration”). The Company has recorded present value of future payments of $515,854 as of December 31, 2015. The Company has recorded interest expense of $37,372 for the year ended December 31, 2015. Security Agreement On the Closing Date, Neuragen entered into a Security Agreement with Knight Canada, pursuant to which Neuragen granted a lien and security interest to Knight Canada in Collateral in connection with the Purchase Agreement. The Security Agreement was made to secure the payment of all indebtedness, obligations and liabilities of Neuragen of the Purchase Agreement, including all expenses and charges, legal or otherwise, suffered or incurred by Knight Canada in collecting or enforcing such indebtedness of the Purchase Agreement. The Security Agreement includes customary events of default, including but not limited to: payment defaults; Neuragen becoming insolvent or entering into bankruptcy; or if any contemplated security ceases to be a valid and perfected first-priority security interest that is not remedied within fifteen business days by Neuragen. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of the outstanding Total Consideration will bear a default interest rate of an additional 10% per annum. The acquisition was treated as an acquisition of assets as the transaction involved the acquisition of a brand and a license agreement. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on June 26, 2015. The Company expects the purchase price allocations for the asset acquisition to be completed by the filing of second quarter 2016 statements. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts Receivable $ 58,054 Inventory 204,925 Intangible property 100,000 License agreement 606,553 Liabilities Accounts Payable (51,795 ) Accrued Expenses (148,520 ) $ 769,217 The intangible property and license agreement will be amortized over their estimated useful lives of 5 years. During the year ended December 31, 2015, the Company charged to operations amortization expense of $70,655. Contribution Agreement with Hand MD Corp.: On August 18, 2015 (the “Closing Date”), we entered into a Contribution Agreement with Hand MD Corp., a Delaware corporation, whereby we contributed to Hand MD Corp. 2,142,857 shares of our common stock in exchange for 50% of Hand MD Corp.’s outstanding capital securities valued at $0.70 per share. Simultaneously, Hand MD, LLC, a California limited liability company, entered into a Contribution Agreement with Hand MD Corp., the principal owners of Hand MD, LLC, and us whereby Hand MD LLC contributed to Hand MD Corp. all of its right, title and interest in its intellectual property associated with skincare, nail care and nail polish products (the “Hand MD Business”) in exchange for the other 50% of Hand MD Corp.’s outstanding capital securities. In the Contribution Agreement among Hand MD Corp., Hand MD, LLC, the principal owners of Hand MD, LLC and us, Hand MD, LLC and its principal owners agreed to not compete or solicit customers or employees for five years. As part of the transaction, we also purchased from Hand MD Corp. all inventory related to the Hand MD Business for approximately $106,000. The Company has recorded 50% of the present value of future royalty payments of $258,897 as of December 31, 2015. We also entered into a license agreement with Hand MD Corp. on August 18, 2015, whereby we acquired the exclusive worldwide license to commercialize Hand MD Corp. skincare products and all improvements thereto. The license runs in perpetuity unless earlier terminated. We will pay Hand MD Corp. a royalty of 5% of the net sales price of product sold, transferred or otherwise disposed of by us, as well as 5% of any amount we receive from sublicensees, subject to a minimum royalty of $250,000 in the second year of the license and $500,000 in the third year of the license, after which the minimum royalty terminates. We are solely responsible for any regulatory and intellectual property filings, including those necessary to maintain regulatory approvals for the licensed products. Either we or Hand MD Corp. can terminate the agreement in the event of bankruptcy or insolvency of the other party, or the uncured material breach of the agreement by the other party. Upon termination we would be entitled to sell any inventory of licensed product in the normal course of business and consistent with sales of licensed product during the term of the agreement. The Contribution Agreements and the License Agreement contain customary representations and warranties and covenants by the respective parties. We also entered into a Consulting Agreement on August 18, 2015, with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related services. We will pay Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. If we terminate the Consulting Agreement without cause, we will be obligated to pay the remaining term of the Agreement. Ms. Harshbarger agreed not to compete with us in the United States in any marketing or sales of skincare, nail polish and nail care products during the term of the Consulting Agreement and for 12 months after its termination. Ms. Harshbarger also agreed not to solicit customers or employees for the same period. The acquisition was treated as an acquisition of assets as the transaction involved the acquisition of a brand and a license agreement. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on August 18, 2015. The Company expects the purchase price allocations for the asset acquisition to be completed during 2016. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Intangible property $ 100,000 License agreement 1,670,675 Liabilities - Royalty payable (258,897 ) Others (11,778 ) $ 1,500,000 The intangible property and license agreement will be amortized over their estimated useful lives of 5 years. During the year ended December 31, 2015, the Company charged to operations amortization expense of $118,045. Stock Purchase Agreement with Breakthrough Products, Inc.: On November 12, 2015 (the “UrgentRx Closing Date”), we entered into a Stock Purchase Agreement (the “UrgentRx SPA”) with Breakthrough Products, Inc., a Delaware corporation (the “Company”), URX ACQUISITION TRUST, a Delaware statutory trust, (the “Trust”), Jordan Eisenberg, the chief executive officer and a shareholder of the Company (“Eisenberg”), and the other shareholders of the Company (Eisenberg and such other shareholders collectively referred to as the “UrgentRx Sellers”) for the purchase of all the issued and outstanding capital stock of the Company for 6,000,000 shares of our common stock (“UrgentRx Equity Consideration”). In addition to the UrgentRx Equity Consideration, we have agreed to pay a royalty to the Trust, for the benefit of the UrgentRx Sellers, equal to 5% of gross sales of the UrgentRx (as defined below) following the first $5,000,000 in gross sales by the UrgentRx Products, on a quarterly basis for a period of seven years from the UrgentRx Closing Date. The Company is engaged in the business of developing and selling medications for headache, heart burn, allergy attack, ache and pain, and upset stomach in the form of powders (“UrgentRx”). Following the UrgentRx Closing Date, we discovered certain liabilities and obligations of Breakthrough that required an adjustment to the UrgentRx Equity Consideration and the royalty payments. On December 17, 2015, we entered into a Settlement and Release Agreement (the “Settlement Agreement”) with the UrgentRx Sellers, the Trust, on its own behalf and as the representative of the UrgentRx Sellers, David T. Leyrer, Michael Valentino, Ron Fugate, and Randall Kaplan (collectively with Leyrer, Valentino, Fugate, the “Former Directors”) to resolve the post-closing liabilities. Pursuant to the terms of the Settlement Agreement, 3,000,000 shares of the Equity Consideration were returned by the Trust to us and our obligation to pay royalties to the Trust was reduced from seven years to five years. The Settlement Agreement further contained mutual releases among us, the UrgentRx Sellers, and the Former Directors, with limited exceptions. Additionally, we issued a three-year warrant to the Trust with a $5.00 per share exercise price. We may redeem the warrant at a price of $0.001 per share if our common stock is traded on the OTCBB or on a national securities exchange, and the per share closing sale price of our common stock equals or exceeds the exercise price for a period of 90 consecutive calendar days. In the event of a reorganization or reclassification of our capital stock, the merger or consolidation of our company into another entity or the sale or transfer of all or substantially all of our assets, the warrant will terminate if not exercised prior to the date of such event. The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on November 12, 2015. The Company expects the purchase price allocations for the acquisition of UrgentRx to be completed during 2016. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 2,298,619 Accounts Receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 3,253,160 Liabilities Accounts Payable (741,822 ) Accrued Expenses (2,202,848 ) $ 2,980,411 The Intellectual property will be amortized over its estimated useful live of 5 years and the non-compete provision will be amortized over its term of 3 years. During the year ended December 31, 2015, the Company charged to operations amortization expense of $4,583. The purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 2,550,000 Stock warrants issued 430,411 Total $ 2,980,411 Pro forma Results of Operations. The historical operating results of the UrgentRx Business prior to its acquisition date have not been included in the Company’s historical consolidated operating results. Pro forma results of operations data (unaudited) for the year ended December 31, 2014 as if the acquisition had occurred on January 1, 2014, are as follows: December 31, 2014 Revenue $ 2,722,288 Net (loss) income (10,621,330 ) The amounts of revenue and net loss of the UrgentRx Business since the acquisition date included in the consolidated statement of operations for the year ended December 31, 2015 are approximately $90,590 and $80,249, respectively. Stock Purchase Agreement with TPR Investments Pty Ltd: On November 15, 2015 (the “Flat Tummy Tea Closing Date”), we entered into a Stock Purchase Agreement (the “Flat Tummy Tea SPA”) with TPR Investments Pty Ltd ACN 128 396 654 as trustee for Polmear Family Trust (the “Flat Tummy Tea Seller”), Timothy Polmear and Rebecca Polmear and NomadChoice Pty Limited ACN 160 729 939 trading as Flat Tummy Tea, an Australian proprietary limited company (“NomadChoice”) for the purchase of all the issued and outstanding capital stock of NomadChoice for $4,000,000 (AUD) in cash consideration (the “Cash Consideration”) and 3,571,428 shares of our common stock (“Flat Tummy Tea Equity Consideration”). In addition to the Cash Consideration and the Flat Tummy Tea Equity Consideration, we have also agreed to pay the Flat Tummy Tea Seller certain earn-out payments of up to $3,500,000 (AUD) in aggregate upon certain EBITDA thresholds are met as of June 30, 2016, as described in the Flat Tummy Tea SPA. This earn-out payment was distributed on March 4, 2016. Flat Tummy Tea is engaged in the business of developing, manufacturing, and selling herbal detox tea (“Flat Tummy Tea”). The Company has accounted for this transaction under the acquisition method of accounting. Under the acquisition method of accounting, the total acquisition consideration price is allocated to the assets acquired and liabilities assumed based on their preliminary estimated fair values based on the management’s estimates as of the date of the acquisition. The Company expects to retain the services of independent valuation firm to determine the fair value of these identifiable intangible assets. Once determined, the Company will reallocate the purchase price of the acquisition based on the results of the independent evaluation if they are materially different from the allocations as recorded on November 1, 2015. The Company expects the purchase price allocations for the acquisition of NomadChoice to be completed during 2016. The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 1,584,642 Other receivable 30,684 Inventory 134,212 Prepaid expenses 141,070 Fixed Assets, net 5,698 Intangible assets, Net 3,493 Blogger Database 200,000 Customer Database 500,000 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 6,174,899 Liabilities Accounts Payable (77,064 ) Accrued Expenses (56,224 ) Dividends Payable (1,177,152 ) Provision for Income Tax (518,558 ) $ 7,095,700 The Blogger Database, Customer Database, Intellectual property and non-compete provision will be amortized over its estimated useful lives of 5 years. During the year ended December 31, 2015, the Company charged to operations amortization expense of $28,333. The purchase price allocated to the acquisition of the assets of NomadChoice is made up as follows: Amount Cash $ 2,848,800 Stock issued at closing 1,750,000 Earn-out payment 2,496,900 Total $ 7,095,700 Pro forma Results of Operations. The historical operating results of the Flat Tummy Tea Business prior to its acquisition date have not been included in the Company’s historical consolidated operating results. Pro forma results of operations data (unaudited) for the year ended December 31, 2014 as if the acquisition had occurred on January 1, 2014, are as follows: December 31, 2014 Revenue $ 2,494,812 Net (loss) income (909,280 ) The Company’s subsidiary Nomad has a fiscal year ended June 30 and the Company’s fiscal year end is December 31. The above proforma information includes revenue and net income of Nomad for the year ended June 30, 2015. The amounts of revenue and net income of the Flat Tummy Tea Business since the acquisition date included in the consolidated statement of operations for the year ended December 31, 2015 are approximately $2,513,990 and $966,671 respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 4 – Income Taxes The Company utilizes FASBASC740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forwards. Based upon Management’s evaluation, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the benefit derived from net operating loss carry-forwards. Deferred income taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not have any uncertain tax positions. Income tax expense for the year ended December 31, 2015 was $389,945, due to Foreign Income Tax relating to NomadChoice in Australia. The table below summarizes the differences between the U.S. statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2015 and 2014: December 31, 2015 December 31, 2014 U.S. Statutory Rate 34 % 34 % U.S. effective rate in excess of AU rate (1 %) - U.S. valuation allowance (34 %) (34 %) Foreign Tax - Australia 6.8 % - Total provision for income taxes 5.8 % - The Company has deferred tax assets, which have been fully reserved, as follows as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Deferred tax assets $ 11,460,536 $ 241,245 Valuation allowance for deferred tax assets (11,460,536 ) (241,245 ) Net deferred tax assets $ - $ - The Company also has net operating loss carryforwards of approximately $25,137,583 included in the deferred tax asset table above attributable to the acquisition of Breakthrough Products, Inc. However, due to limitations of carryover attributes and separate return limitation year rules, it is unlikely the company will benefit from these NOL and thus Management has determined a 100% valuation reserved is required. Further, the Company has not completed an evaluation of the NOL’s attributable to Breakthrough Products, Inc. at the date of this report. The total deferred tax asset is calculated by multiplying a domestic (US) 34 percent marginal tax rate by the cumulative Net Operating Loss Carryforwards (“NOL”).The Company currently has net operating loss carryforwards approximately aggregating $33,707,458, which expire through 2035. The deferred tax asset related to the NOL carryforwards Management has determined based on all the available information that a 100% Valuation reserve is required. The Company has not completed its evaluation of NOL Utilization Limitations under IRC Section 382, change of ownership rules. If the Company has had a change in ownership the NOL’s would be limited as to the amount that could be utilized each year, based on the Internal Revenue Code, as amended.” The Company has not filed its Federal and State income tax returns. Such income tax returns remain subject to examination by federal and most state tax authorities.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following: December 31, 2015 December 31, 2014 Trade accounts receivable $ 4,101,148 $ 2,898 Less allowances (121,291 ) - Total accounts receivable, net $ 3,979,857 $ 2,898 During the year ended December 31, 2015, the Company charged $50,000 to bad debt expense in setting up an allowance.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets [Abstract]
Prepaid Expenses	Note 6 – Prepaid Expenses At December 31, 2015 and 2014, prepaid expenses consisted of the following: December 31, 2015 December 31, 2014 Advances for inventory $ 171,494 $ - Media production 55,849 - Insurance 54,519 10,000 Trade shows 45,700 - Deposits 41,228 - Consultants 24,000 - Rent 16,216 - Miscellaneous 13,428 - Total $ 422,434 $ 10,000

Concentration of Credit Risk

Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	Note 7 – Concentration of Credit Risk Cash and cash equivalents The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2015, the uninsured balance amounted to $3,453,290. Accounts receivable As of December 31, 2015, one customer accounted for 78% of the Company’s accounts receivable. Major customers For the year ended December 31, 2015, two customers accounted for approximately 71% of the Company’s gross revenues. Substantially all of the Company’s business is with companies in the United States. Major suppliers For the year ended December 31, 2015, our products were made by the following suppliers: FOCUSfactor Pittsburgh, PA Tustin, CA Flat Tummy Tea Highland, NY - Neuragen Linthicum Heights, MD - UrgentRx Ogden, UT - It is the opinion of management that the products can be produced by other manufacturers and the choice to utilize these suppliers is not a significant concentration.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Note 8 – Inventory Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. The carrying value of inventory consisted of the following: December 31, 2015 December 31, 2014 Finished goods $ 535,908 $ - Components 115,340 - Raw Materials 35,406 - Energy product - 26,064 Total inventory $ 686,654 $ 26,064 As of January 22, 2015, inventory was pledged to Knight under the Loan Agreement (see note 12).

Fixed Assets and Intangible Ass

Fixed Assets and Intangible Assets	12 Months Ended
	Dec. 31, 2015
Assets
Fixed Assets and Intangible Assets	Note 9 – Fixed Assets and Intangible Assets As of December 31, 2015 and 2014, fixed assets and intangible assets consisted of the following: December 31, 2015 December 31, 2014 Property and equipment $ 18,187 $ - Less accumulated depreciation (6,170 ) - Fixed assets, net $ 12,017 $ - Depreciation expense for the years ended December 31, 2015 and 2014 was $1,513 and $0, respectively. December 31, 2015 December 31, 2014 FOCUSfactor intellectual property $ 1,000,000 $ - Intangible assets subject to amortization 5,521,751 - Less accumulated amortization (606,489 ) - Intangible assets, net $ 5,915,262 $ - Amortization expense for the years ended December 31, 2015 and 2014 was $606,489 and $0, respectively. These intangible assets were acquired through Asset Purchase Agreement and Stock Purchase Agreements disclosed in Note 3. The estimated aggregate amortization expense over each of the next five years is as follows: 2016 $ 1,111,229 2017 1,111,229 2018 1,109,070 2019 1,094,329 2020 489,405

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 – Related Party Transactions On April 2, 2014, the Company granted 1,000,000 options valued at approximately $282,000 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company (see note 15). On October 31, 2014, the Company borrowed $100,000 through a promissory note bearing interest at 10% with a maturity date of October 31, 2015 from a company owned by Mr. Ross, the Company’s Chief Executive Officer. During the year ended December 31, 2015, the note was converted into 400,000 shares of the Company’s common stock. The Company accrued and paid consulting fees of $15,000 per month to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $180,000 as consulting fees and made payments totaling $486,958 towards services to an entity owned and controlled by an officer and shareholder of the Company for the year ended December 31, 2015. As of December 31, 2015, the total outstanding balance was $0. At December 31, 2014, $16,077, was due from a company owned by Mr. Jack Ross, Chief Executive Officer of the Company in a form of an advance in the normal course of business. On January 22, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for the purchase of the Focus Factor assets. At December 31, 2015, the Company owed Knight $4,267,268 on this loan, net of discount (see Note 12). On June 26, 2015, the Company entered into a Security Agreement with Knight Therapeutics, Inc., through its wholly owned subsidiary Neuragen Corp., for the purchase of Knight Therapeutics, Inc.’s assets. At December 31, 2015, the Company owed Knight $925,000 in relation to this agreement (see Note 12). On August 18, 2015, the Company entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related service. The Company will pay Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. Hand MD, LLC is a 50% owner in Hand MD Corp. The Company expensed $40,000 through payroll for the year ended December 31, 2015. As of December 31, 2015, the total outstanding balance was $0. On November 12, 2015, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for the purchase of NomadChoice Pty Limited and Breakthrough Products, Inc. At December 31, 2015, the Company owed Knight $3,571,314 on this loan, net of discount (see Note 12). At December 31, 2015, NomadChoice Pty Ltd. (subsidiary) of the Company owed Knight Therapeutics $71,573 in connection with a royalty distribution agreement (see Note 3).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 11 – Accounts Payable and Accrued Liabilities As of December 31, 2015 and 2014, accounts payable and accrued liabilities consisted of the following: December 31, 2015 December 31, 2014 Payroll $ 128,237 $ 10,867 Legal fees 38,752 47,916 Manufacturers 1,527,333 - Promotions 1,213,021 - Returns allowance 1,128,133 - Customers 411,033 Interest 110,754 - Royalties 71,573 - Warehousing 31,748 - Others 371,518 15,859 Total $ 5,032,102 $ 74,642

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	Note 12 – Notes Payable The Company’s loans payable at December 31, 2015 and 2014 are as follows: December 31, 2015 December 31, 2014 Loans payable $ 12,406,589 $ - Unamortized debt discount (2,536,419 ) - Total 9,870,170 - Less: Current portion (3,912,060 ) - Long-term portion $ 5,958,110 $ - $6,000,000 January 22, 2015 Loan: On January 22, 2015, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan the Company $6.0 million (the “Loan”), and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring the Focus Factor Business (defined below). At closing, the Company paid Knight an origination fee of $120,000 and a work fee of $60,000 and also paid $40,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year; provided, however, that upon the occurrence of an equity or convertible equity offering by the Company of at least $1.0 million, the interest rate will drop to 13% per year. Interest accrues quarterly and is payable in arrears on March 31, June 30, September 30 and December 31 in each year, beginning on March 31, 2015. All outstanding principal and accrued and unpaid interest is due on the earliest to occur of either January 20, 2017 (the “Maturity Date”), or the date that Knight, in its discretion, accelerates the Company’s obligations due to an event of default. The Company may extend the Maturity Date for two successive additional 12-month periods if at March 31, 2016 and March 31, 2017, respectively, the Company’s revenues exceed $13.0 million and its EBITDA exceeds $2.0 million for the respective 12-month period then ending. Principal payments under the Loan Agreement commenced on June 30, 2015 and continue quarterly as set forth on the Repayment Schedule to the Loan Agreement. Subject to certain restrictions, the Company may prepay the outstanding principal of the Loan (in whole but not in part) at any time if the Company pays a concurrent prepayment fee equal to the greater of (i) the total unpaid annual interest that would have been payable during the year in which the prepayment is made if the prepayment is made prior to the first anniversary of the closing, and (ii) $300,000. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in all present and future assets of the Company. The Company also agreed to not pledge or otherwise encumber its intellectual property assets, subject to certain customary exceptions. The Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to the Company’s business and the aggregate consideration to be paid does not exceed $100,000) or make capital expenditures in excess of $100,000 over the Company’s annual business plan in any year. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect default. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of the Loan will bear a default interest rate of an additional 5%. In connection with the Loan Agreement, the Company issued to Knight a warrant that entitled Knight to purchase 4,595,187 shares of common stock of the Company (“Common Stock”) on or prior to close of business on January 30, 2015 (the “ST Warrant”). The aggregate exercise price of the Common Stock under the ST Warrant is $1.00. Knight exercised the ST Warrant on January 22, 2015. Also in connection with the Loan Agreement, the Company issued to Knight a warrant to purchase 3,584,759 shares of Common Stock on or prior to the close of business of January 22, 2025 (the “LT Warrant”). The exercise price per share of the Common Stock under the LT Warrant is $0.34. The LT Warrant provides for cashless exercise. The LT Warrant also provides that in the event the closing price of the Common Stock remains above $1.00 for six consecutive months, Knight will forfeit the difference between the number of shares acquired under the LT Warrant prior to 90 days after such six-month period, and 25% of the shares purchasable under the LT Warrant. The beneficial conversion feature of the warrants issued to the noteholders amounted to $1,952,953 (ST warrants) and $1,462,560 (LT warrants), respectively, and was recorded as debt discount of the corresponding debt. The Company recognized amortization of debt discount of $1,952,953 (ST warrants) and $854,828 (LT warrants) during the year ended December 31, 2015. Unamortized debt discount as of December 31, 2015 amounted to $607,732. The Company also recorded deferred financing costs of $289,045 with respect to the above loan. The Company recognized amortization of deferred financing costs of $136,207 during the year ended December 31, 2015. The Company recognized and paid interest expense of $805,686 during the year ended December 31, 2015. Accrued interest expense was $0 as of December 31, 2015. Loan payable balance was $4,875,000 as of December 31, 2015. $1,500,000 January 22, 2015 Loan: On January 22, 2015, the Company issued a 0% promissory note in a principal amount of $1,500,000 in connection with an Asset Purchase Agreement (see note 1). The note has a maturity date of January 20, 2017, with $750,000 to be paid on or before January 20, 2016 and an additional $750,000 to be paid on or before January 20, 2017. Loan payable balance was $1,500,000 as of December 31, 2015. $950,000 June 26, 2015 Security Agreement: On June 26, 2015, the Company, through its wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000 in connection with an Asset Purchase Agreement (see note 1). The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million. The Company also recorded deferred financing costs of $10,486 with respect to the above agreement. The Company recognized amortization of deferred financing costs of $2,643 during the year ended December 31, 2015. The balance at December 31, 2015 was $925,000. $5,500,000 November 12, 2015 Loan: On November 12, 2015, we entered into a First Amendment to Loan Agreement (“First Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $5.5 million, and which amount was borrowed at closing (the “Financing”) for the purpose of acquiring Breakthrough Products, Inc. and NomadChoice Pty Limited through Stock Purchase Agreements. At closing, we paid Knight an origination fee of $110,000 and a work fee of $55,000 and also paid $24,000 of Knight’s expenses associated with the Loan. The Loan bears interest at a rate of 15% per year. The interest rate will decrease to 13% if we meet certain equity-fundraising targets. The New Loan Agreement matures on November 11, 2017. In connection with the New Loan Agreement, we issued Knight a warrant that entitles Knight to purchase 5,550,625 shares of our common stock (“Knight Warrant Shares”) representing approximately 6.5% of our fully diluted capital, which Knight exercised in full on November 12, 2015. Knight also received a 10-year warrant entitling Knight to purchase up to 4,547,243 shares of our common stock at $0.49 per share (“Knight Warrants”). The beneficial conversion feature of the warrants issued to the noteholders amounted to $2,553,287 (5,550,625 warrants) and $2,067,258 (4,547,243 warrants), respectively, and was recorded as debt discount of the corresponding debt. For derivative liability calculation on 4,547,243 warrants, refer to Note 17. The Company recognized amortization of debt discount of $2,553,287 (5,550,625 warrants) and $138,571 (4,547,243 warrants) during the year ended December 31, 2015. Unamortized debt discount as of December 31, 2015 amounted to $1,928,686. The Company also recorded deferred financing costs of $233,847 with respect to the above loan. The Company recognized amortization of deferred financing costs of $15,675 during the year ended December 31, 2015. The Company recognized interest expense of $110,753 during the year ended December 31, 2015. Accrued interest expense was $110,753 as of December 31, 2015. The balance at December 31, 2015 was $5,500,000.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Deficit	Note 13 – Stockholders’ Deficit The total number of shares of all classes of capital stock which the Company is authorized to issue is 75,000,000 shares of common stock with $0.00001 par value. On July 30, 2014, the Company’s board of directors approved an increase of the Company’s authorized common stock from 75,000,000 to 300,000,000 shares, which increase was approved by the Company’s shareholders and became effective on August 5, 2015. On April 17, 2014, upon approval from FINRA, the Company effected a 30 for 1 forward stock split by way of a stock dividend, of all of its issued and outstanding shares of common stock (the “Stock Split”). The Stock Split did not affect the number of the Company’s authorized common stock or its par value. All references in the accompanying consolidated financial statements and notes thereto have been retroactively restated to reflect the stock split. During the year ended December 31, 2015, the Company issued 4,595,187 shares of its common stock upon exercise of the ST Warrant at an aggregate exercise price of $1.00 in connection with the Loan Agreement (see note1). During the year ended December 31, 2015, the Company issued 5,550,625 shares of its common stock upon exercise of a Warrant at an aggregate exercise price of $1.00 in connection with the Loan Agreement (see note1). During the year ended December 31, 2015, the Company issued 400,000 shares of its common stock to a note holder in a note conversion at $0.25 per share. At the time of conversion, the note was valued at $100,000 for outstanding principal. During the year ended December 31, 2015, the Company issued 2,142,857 shares of its common stock valued at $0.70 per share in accordance with Contribution Agreement entered into with Hand MD Corp. in exchange for 50% of Hand MD Corp.’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 3,571,428 shares of its common stock valued at $0.35 per share in accordance with a stock purchase agreement entered into with NomadChoice Pty Limited in exchange for 100% of NomadChoice Pty Limited’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 3,000,000 shares of its common stock valued at $0.85 per share in accordance with a stock purchase agreement entered into with Breakthrough Products, Inc. in exchange for 100% of Breakthrough Product Inc.’s outstanding capital securities. During the year ended December 31, 2015, the Company issued 40,000 shares of its common stock valued at $0.65 per share for cash. During the year ended December 31, 2015, the Company issued 292,857 shares of its common stock valued at $0.70 per share to settle accounts payable. On April 21, 2014, the Company entered into an agreement with accredited investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $0.25 per share, for an aggregate consideration of $500,000. During the year ended December 31, 2014, the Company cancelled 135,900,000 shares of its common stock (4,530,000 pre-Stock Split) as part of the Merger transaction. During the year ended December 31, 2014, the Company issued 16,000,000 shares of its common stock valued at $25,000 as part of the Merger Agreement. During the year ended December 31, 2015 and 2014, the Company committed to issue common stock valued at $28,000 and $40,000, respectively for services rendered. As of December 31, 2015 and 2014, there were 81,692,954 and 62,100,000 shares of the Company’s common stock issued and outstanding, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Litigation: From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations. Operating leases In April 2014, a subsidiary entered into an extension of a non-cancellable operating lease for office space that expires on March 31, 2017. Rent expense under this lease for the period from acquisition until December 31, 2015 was $8,923 per month less a $3,010 per month sublease through March 2017. In December 2015, a subsidiary entered into a non-cancellable operating lease for office space through November 2016. Rental payments under this lease are $5,500 Australian dollars per month, which is approximately $4,200. In December 2015, the Company entered into a non-cancellable operating lease for office space through December 2016. Rental payments under this lease are $5,500 per month. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: Year ending December 31: 2016 $ 220,676 2017 27,294 Total $ 247,970 On December 8, 2014, a subsidiary entered into a non-cancellable 36 month phone lease with an estimated cost of $894 a month. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: Year ending December 31: 2016 $ 10,728 2017 9,834 Total $ 20,562

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	Note 15 – Stock Options On July 30, 2014, the Company’s board of directors approved the Company’s 2014 Equity Incentive Plan and the reservation of 15,525,000 shares of common stock for issuance under such plan. Such plan was approved by the Company’s shareholders and became effective on August 5, 2015. On April 2, 2014, the Company granted 1,000,000 options with an exercise price of $0.25 per share to the Company owned by Mr. Jack Ross, Chief Executive Officer of the Company. On December 14, 2015, the Company granted 1,000,000 options each with an exercise price of $0.25 per share to two Board Members of the Company. On December 14, 2015, the Company granted 1,000,000 options each with an exercise price of $0.65 per share to two employees of the Company. The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2015: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.25 - $0.65 5,000,000 8.62 $ 0.41 3,000,000 $ 0.25 The stock option activity for the year ended December 31, 2015 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 1,000,000 $ 0.25 Granted 4,000,000 0.45 Exercised - - Expired or canceled - - Outstanding at December 31, 2015 5,000,000 $ 0.41 Stock-based compensation expense related to vested options was $523,714 and $282,247 during the years ended December 31, 2015 and 2014, respectively. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2015 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.74, risk-free interest rate of 2.23%, volatility of 154%, expected lives of 10 years, and dividend yield of 0%. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2014 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.33, risk-free interest rate of 1.8%, volatility of 125%, expected lives of 4.5 years, and dividend yield of 0%. Stock options outstanding as of December 31, 2015, as disclosed in the above table, have an intrinsic value of $1,400,000.

Stock Warrants

Stock Warrants	12 Months Ended
	Dec. 31, 2015
Stock Warrants
Stock Warrants	Note 16 – Stock Warrants The following table summarizes the warrants outstanding and the related prices for the shares of the Company’s common stock at December 31, 2015: Warrants Outstanding Warrants Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.34 3,584,759 9.1 $ 0.34 3,584,759 $ 0.34 0.49 4,547,243 9.9 0.49 4,547,243 0.49 5.00 1,000,000 3 5.00 1,000,000 5.00 The warrant activity for the year ended December 31, 2015 is as follows: Warrants Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 - $ - Granted 19,277,814 0.44 Exercised (10,145,812 ) 0.00000020 Expired or canceled - - Outstanding at December 31, 2015 9,132,002 $ 0.92

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Note 17 – Derivatives The Company has incurred a liability for the estimated fair value of a derivative warrant instrument. The estimated fair value of the derivative warrant instruments has been calculated using the Black-Scholes fair value option-pricing model with key input variables provided by management, as of the issue date, with the valuation offset against additional paid in capital, and at each reporting date, with changes in fair value recorded as gains or losses on revaluation in non-operating income (expense). The Company identified embedded derivatives related to the warrants issued along with loan payable entered into in November 2015. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivatives as of the inception date of the warrants and to adjust the fair value as of each subsequent balance sheet date. At the inception of the warrants, the Company determined a fair value of $2,067,258 of the embedded derivative. The fair value of the embedded derivative was determined using the Black-Scholes Model based on the following assumptions: November 12, 2015 Risk-free interest rate 2.32 % Expected remaining term 10 Years Expected volatility 157.56 % Dividend yield 0 % The initial fair values of the embedded derivative of $2,067,258 was allocated as a debt discount $2,067,258. Fair value at December 31, 2015 was estimated to be $3,096,179 and based on the following assumptions: December 31, 2015 Risk-free interest rate 2.27 % Expected remaining term 9.75 Years Expected volatility 152.07 % Dividend yield 0 % During the year ended December 31, 2015, the increase in the fair value of the warrant derivative liability of $1,028,921 was recorded as a loss on change in fair value of derivative liability.

Segments

Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segments	Note 18 – Segments Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis. Net sales attributed to customers in the United States and foreign countries for the years ended December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 United States $ 13,129,753 $ 9,158 Foreign countries 326,624 - $ 13,456,377 $ 9,158 The Company’s net sales by product group for the years ended December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Focus Factor $ 10,482,367 $ - Flat Tummy Tea 2,513,990 - Other (1) 460,020 9,158 $ 13,456,377 $ 9,158 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales. Long-lived assets (net) attributable to operations in the United States and foreign countries as of December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 United States $ 17,451,598 $ - Foreign countries 12,081 - $ 17,463,679 $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events Management evaluated all activities of the Company through the issuance date of the Company’s consolidated financial statements and concluded that no subsequent events have occurred that would require adjustments or disclosure into the consolidated financial statements.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2015 and 2014 significant estimates included in these estimates are assumptions about collection of accounts receivable, useful life of fixed and intangible assets, goodwill and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, stock based compensation, risk-free interest rate, and expected dividend rate.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2015 the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2015, the uninsured balance amounted to $3,453,290.
Capitalization of Fixed Assets	Capitalization of Fixed Assets The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit.
Accounts Receivable	Accounts receivable Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts.
Advertising Expense	Advertising Expense The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying consolidated statements of operations.
Research and Development	Research and Development Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred.
Income Taxes	Income Taxes The Company utilizes FASBASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration. NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) Per Common Share The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of December 31, 2015, options to purchase 5,000,000 shares of common stock and warrants to purchase 9,132,002 shares of common stock were outstanding these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.
Going Concern	Going Concern The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at December 31, 2015 of $8,569,841. The Company had a working capital deficit of $6,165,812 as of December 31, 2015. Due to acquisitions during 2015 of revenue-producing products, the Company believes it has established an ongoing source of revenue that is sufficient to cover its operating costs. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. If the Company is unable to obtain adequate capital it could be forced to cease development of operations. In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Fair Value Measurements	Fair Value Measurements The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure. ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 - Unobservable inputs for the asset or liability. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. As of December 31, 2015, the Company has determined that there were no assets or liabilities measured at fair value except for the warrant derivative liability which is valued using Level 3 estimates.
Inventory	Inventory Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items.
Stock-Based Compensation	Stock-Based Compensation The Company adopted the provisions of ASC 718. We estimate the fair value of stock options using a binomial model, consistent with the provisions of ASC 718 and SEC Staff Accounting Bulletin No. 107, Share-Based Payment. Option-pricing models require the input of highly subjective assumptions, including the price volatility of the underlying stock. We determined that the use of implied volatility is expected to be more reflective of market conditions and, therefore, could reasonably be expected to be a better indicator of our expected volatility than historical volatility. The expected term assumption used in calculating the estimated fair value of our stock-based compensation awards using the Black-Scholes-Merton (BSM) model is based on detailed historical data about employees’ exercise behavior, vesting schedules, and death and disability probabilities. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. We estimate the forfeiture rate based on historical experience of our stock-based awards that are granted, exercised and cancelled. We believe the resulting BSM calculation provides a more refined estimate of the fair value of our employee stock options.
Long-lived Assets	Impairment of Long-Lived Assets When facts and circumstances indicate that the carrying values of long-lived assets, including fixed assets, may be impaired, an evaluation of recoverability is performed by comparing the carrying value of the assets to projected future cash flows in addition to other quantitative and qualitative analyses. Upon indication that the carrying value of such assets may not be recoverable, the Company recognizes an impairment loss as a charge against current operations. Long-lived assets to be disposed of are reported at the lower of the carrying amount or fair value, less estimated costs to sell. The Company makes judgments related to the expected useful lives of long-lived assets and its ability to realize undiscounted cash flows in excess of the carrying amounts of such assets which are affected by factors such as the ongoing maintenance and improvements of the assets, changes in economic conditions and changes in operating performance. As the Company assesses the ongoing expected cash flows and carrying amounts of its long-lived assets, these factors could cause the Company to realize a material impairment charge.
Goodwill	Goodwill An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of December 31, 2015 our qualitative analysis of goodwill did not indicate any impairment.
Foreign Currency Translation	Foreign Currency Translation The functional currency of each of the Company’s foreign subsidiaries is the U.S. Dollar. The Company’s subsidiary maintains its record using local currency (Australian Dollar). All monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at fiscal year-end exchange rates, non-monetary assets and liabilities of foreign subsidiaries were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary.
Concentrations of Credit Risk	Concentrations of Credit Risk In the normal course of business, the Company provided credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns.
Warehousing costs	Warehousing costs Warehouse costs include all third party warehouse rent fees and any additional costs relating to assembly or special pack-outs of the Company products are charged to general and administrative expenses as incurred.
Product display costs	Product display costs All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to general and administrative expenses as incurred.
Warrant Derivative Liabilities	Warrant Derivative Liabilities ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. A Black-Scholes-Merton option-pricing model, with dilution effects, was utilized to estimate the fair value of the Warrant Derivative Liabilities as of November 12, 2015 and December 31, 2015. This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 Stock Price $ 0.46 $ 0.69 Exercise Price $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 Stock Volatility 157.56 % 152.07 % Risk-Free Rate 2.32 % 2.27 % Dividend Rate 0 % 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243
Cost of Sales	Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are capitalized and are being amortized to interest expense over the term of the related debt facilities.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets When facts and circumstances indicate that the carrying values of long-lived assets, including fixed assets, may be impaired, an evaluation of recoverability is performed by comparing the carrying value of the assets to projected future cash flows in addition to other quantitative and qualitative analyses. Upon indication that the carrying value of such assets may not be recoverable, the Company recognizes an impairment loss as a charge against current operations. Long-lived assets to be disposed of are reported at the lower of the carrying amount or fair value, less estimated costs to sell. The Company makes judgments related to the expected useful lives of long-lived assets and its ability to realize undiscounted cash flows in excess of the carrying amounts of such assets which are affected by factors such as the ongoing maintenance and improvements of the assets, changes in economic conditions and changes in operating performance. As the Company assesses the ongoing expected cash flows and carrying amounts of its long-lived assets, these factors could cause the Company to realize a material impairment charge.
Shipping Costs	Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses.
Related parties	Related parties Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The All transactions with related parties shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party.
Segment Reporting	Segment Reporting Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements ASU 2015-03 In April 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. The Company is evaluating the possible effect of this guidance on its financial statements. ASU 2015-02 In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows. ASU 2015-01 In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-17 In November 2014, the FASB issued ASU No. 2014-17, “Business Combinations (Topic 805): Pushdown Accounting.” This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows. ASU 2014-16 In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not currently have issued, nor are we investors in, hybrid financial instruments. Accordingly, we do not expect the adoption of ASU 2014-16 to have any effect on our financial position, results of operations or cash flows. ASU 2014-15 In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40)”. ASU 2014-15 provides guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-12 In June 2014, the FASB issued ASU No. 2014-12, “Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not expect the adoption of ASU 2014-12 to have a material effect on our financial position, results of operations or cash flows. ASU 2014-09 In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are still evaluating the effect of the adoption of ASU 2014-09. On April 1, 2015, the FASB voted to propose to defer the effective date of the new revenue recognition standard by one year. ASU 2014-08 In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) and Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” ASU 2014-08 amends the definition for what types of asset disposals are to be considered discontinued operations, as well as amending the required disclosures for discontinued operations and assets held for sale. ASU 2014-08 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014. The adoption of ASU 2014-08 did not have any effect on our financial position, results of operations or cash flows. There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed financial position, results of operations or cash flows.
Change in Fiscal Year End	Change in Fiscal Year End On April 21, 2014, the Company’s board of directors approved a change to the Company’s fiscal year end from July 31 to December 31 of each year.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Assumptions Used for Fair Value of Warrant Derivative Liabilities	A Black-Scholes-Merton option-pricing model, with dilution effects, was utilized to estimate the fair value of the Warrant Derivative Liabilities as of November 12, 2015 and December 31, 2015. This model is subject to the significant assumptions discussed below and requires the following key inputs with respect to the Company and/or instrument: Input November 12, 2015 December 31, 2015 Stock Price $ 0.46 $ 0.69 Exercise Price $ 0.49 $ 0.49 Expected Life (in years) 10.0 9.75 Stock Volatility 157.56 % 152.07 % Risk-Free Rate 2.32 % 2.27 % Dividend Rate 0 % 0 % Outstanding Shares of Common Stock 4,547,243 4,547,243

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts Receivable $ 2,733,167 Inventory 67,113 Intellectual Property 1,000,000 Non-compete provision 50,000 Non-solicitation provision 50,000 Intangible assets-Customer relationships 1,941,030 Goodwill 2,071,517 Liabilities Accounts Payable (971,381 ) Accrued Expenses (941,446 ) $ 6,000,000
Purchase Price Allocated to Acquisition of Assets	The purchase price allocated to the acquisition of the assets of Factor Nutrition Labs, LLC is made up as follows: Amount Cash payment made on January 22, 2015 $ 4,500,000 Cash payment to be made on January 20, 2016 750,000 Cash payment to be made on January 20, 2017 750,000 Total $ 6,000,000
Pro forma Results of Acquisition	Pro forma results of operations data (unaudited) for the years ended December 31, 2014 and 2013, as if the acquisition had occurred on January 1, 2013, are as follows: December 31, 2014 2013 Revenue $ 12,695,295 $ 10,629,171 Net (loss) income (183,471 ) 932,209
Knight Therapeutics Inc [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Accounts Receivable $ 58,054 Inventory 204,925 Intangible property 100,000 License agreement 606,553 Liabilities Accounts Payable (51,795 ) Accrued Expenses (148,520 ) $ 769,217
Hand MD LLC [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Intangible property $ 100,000 License agreement 1,670,675 Liabilities - Royalty payable (258,897 ) Others (11,778 ) $ 1,500,000
Breakthrough Products, Inc [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values		The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 2,298,619 Accounts Receivable (68,976 ) Inventory 234,709 Prepaid expenses 57,569 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 3,253,160 Liabilities Accounts Payable (741,822 ) Accrued Expenses (2,202,848 ) $ 2,980,411
Purchase Price Allocated to Acquisition of Assets		The purchase price allocated to the acquisition of the assets of UrgentRx is made up as follows: Amount Stock payment $ 2,550,000 Stock warrants issued 430,411 Total $ 2,980,411
Pro forma Results of Acquisition		Pro forma results of operations data (unaudited) for the year ended December 31, 2014 as if the acquisition had occurred on January 1, 2014, are as follows: December 31, 2014 Revenue $ 2,722,288 Net (loss) income (10,621,330 )
TPR Investments Pty Ltd [Member]
Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values	The preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows: Assets Cash $ 1,584,642 Accounts Receivable 30,684 Inventory 77,069 Prepaid expenses 141,070 Fixed Assets, net 5,698 Intangible assets, Net 3,493 Blogger Database 200,000 Customer Database 500,000 Intellectual property 100,000 Non-compete provision 50,000 Goodwill 6,214,899 Liabilities Accounts Payable (77,064 ) Accrued Expenses (56,224 ) Dividends Payable (1,177,152 ) Provision for Income Tax (501,415 ) $ 7,095,700
Purchase Price Allocated to Acquisition of Assets	The purchase price allocated to the acquisition of the assets of NomadChoice is made up as follows: Amount Cash $ 2,848,800 Stock issued at closing 1,750,000 Earn-out payment 2,496,900 Total $ 7,095,700
Pro forma Results of Acquisition	Pro forma results of operations data (unaudited) for the year ended December 31, 2014 as if the acquisition had occurred on January 1, 2014, are as follows: December 31, 2014 Revenue $ 2,494,812 Net (loss) income (909,280 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The table below summarizes the differences between the U.S. statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2015 and 2014: December 31, 2015 December 31, 2014 U.S. Statutory Rate 34 % 34 % U.S. effective rate in excess of AU rate (1 %) - U.S. valuation allowance (34 %) (34 %) Foreign Tax - Australia 6.8 % - Total provision for income taxes 5.8 % -
Schedule of Deferred Income Tax Assets	The Company has deferred tax assets, which have been fully reserved, as follows as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Deferred tax assets $ 11,460,536 $ 241,245 Valuation allowance for deferred tax assets (11,460,536 ) (241,245 ) Net deferred tax assets $ - $ -

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Accounts Receivable, Net of Allowances	Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following: December 31, 2015 December 31, 2014 Trade accounts receivable $ 4,101,148 $ 2,898 Less allowances (121,291 ) - Total accounts receivable, net $ 3,979,857 $ 2,898

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Prepaid Expense and Other Assets [Abstract]
Summary of Prepaid Expenses	At December 31, 2015 and 2014, prepaid expenses consisted of the following: December 31, 2015 December 31, 2014 Advances for inventory $ 171,494 $ - Media production 55,849 - Insurance 54,519 10,000 Trade shows 45,700 - Deposits 41,228 - Consultants 24,000 - Rent 16,216 - Miscellaneous 13,428 - Total $ 422,434 $ 10,000

Concentration of Credit Risk (T

Concentration of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Summary of Major Suppliers	For the year ended December 31, 2015, our products were made by the following suppliers: FOCUSfactor Pittsburgh, PA Tustin, CA Flat Tummy Tea Highland, NY - Neuragen Linthicum Heights, MD - UrgentRx Ogden, UT -

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Carrying Value of Inventory	The carrying value of inventory consisted of the following: December 31, 2015 December 31, 2014 Finished goods $ 535,908 $ - Components 115,340 - Raw Materials 35,406 - Energy product - 26,064 Total inventory $ 686,654 $ 26,064

Fixed Assets and Intangible A34

Fixed Assets and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Assets
Summary of Fixed and Intangible Assets	As of December 31, 2015 and 2014, fixed assets and intangible assets consisted of the following: December 31, 2015 December 31, 2014 Property and equipment $ 18,187 $ - Less accumulated depreciation (6,170 ) - Fixed assets, net $ 12,017 $ - Depreciation expense for the years ended December 31, 2015 and 2014 was $1,513 and $0, respectively. December 31, 2015 December 31, 2014 FOCUSfactor intellectual property $ 1,000,000 $ - Intangible assets subject to amortization 5,521,751 - Less accumulated amortization (606,489 ) - Intangible assets, net $ 5,915,262 $ -
Summary of Estimated Aggregate Amortization Expense	The estimated aggregate amortization expense over each of the next five years is as follows: 2016 $ 1,111,229 2017 1,111,229 2018 1,109,070 2019 1,094,329 2020 489,405

Accounts Payable and Accrued 35

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As of December 31, 2015 and 2014, accounts payable and accrued liabilities consisted of the following: December 31, 2015 December 31, 2014 Payroll $ 128,237 $ 10,867 Legal fees 38,752 47,916 Manufacturers 1,527,333 - Promotions 1,213,021 - Returns allowance 1,128,133 - Customers 411,033 Interest 110,754 - Royalties 71,573 - Warehousing 31,748 - Others 371,518 15,859 Total $ 5,032,102 $ 74,642

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Loan Payable	The Company’s loans payable at December 31, 2015 and 2014 are as follows: December 31, 2015 December 31, 2014 Loans payable $ 12,406,589 $ - Unamortized debt discount (2,536,419 ) - Total 9,870,170 - Less: Current portion (3,912,060 ) - Long-term portion $ 5,958,110 $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Future Minimum Rental Payments For Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: Year ending December 31: 2016 $ 220,676 2017 27,294 Total $ 247,970
Subsidiary [Member]
Schedule of Future Minimum Rental Payments For Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2015: Year ending December 31: 2016 $ 10,728 2017 9,834 Total $ 20,562

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Options Outstanding by Price Range	The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2015: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.25 - $0.65 5,000,000 8.62 $ 0.41 3,000,000 $ 0.25
Schedule of Stock Options Activity	The stock option activity for the year ended December 31, 2015 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 1,000,000 $ 0.25 Granted 4,000,000 0.45 Exercised - - Expired or canceled - - Outstanding at December 31, 2015 5,000,000 $ 0.41

Stock Warrants (Tables)

Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2015
Stock Warrants
Summary of Warrants Outstanding by Price Range	The following table summarizes the warrants outstanding and the related prices for the shares of the Company’s common stock at December 31, 2015: Warrants Outstanding Warrants Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $ 0.34 3,584,759 9.1 $ 0.34 3,584,759 $ 0.34 0.49 4,547,243 9.9 0.49 4,547,243 0.49 5.00 1,000,000 3 5.00 1,000,000 5.00
Schedule of Stock Warrants Activity	The warrant activity for the year ended December 31, 2015 is as follows: Warrants Outstanding Weighted Average Exercise Price Outstanding at December 31, 2014 - $ - Granted 19,277,814 0.44 Exercised (10,145,812 ) 0.00000020 Expired or canceled - - Outstanding at December 31, 2015 9,132,002 $ 0.92

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Assumptions Used For Fair Value of Derivative	The fair value of the embedded derivative was determined using the Black-Scholes Model based on the following assumptions: November 12, 2015 Risk-free interest rate 2.32 % Expected remaining term 10 Years Expected volatility 157.56 % Dividend yield 0 % Fair value at December 31, 2015 was estimated to be $3,096,179 and based on the following assumptions: December 31, 2015 Risk-free interest rate 2.27 % Expected remaining term 9.75 Years Expected volatility 152.07 % Dividend yield 0 %

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Summary of Net Sales Attributed to Customers Geographical Segment	Net sales attributed to customers in the United States and foreign countries for the years ended December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 United States $ 13,129,753 $ 9,158 Foreign countries 326,624 - $ 13,456,377 $ 9,158
Summary of Net Sales Attributed to Customers Product Group	The Company’s net sales by product group for the years ended December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 Focus Factor $ 10,482,367 $ - Flat Tummy Tea 2,513,990 - Other (1) 460,020 9,158 $ 13,456,377 $ 9,158 (1) Net sales for any other product group of similar products are less than 10% of consolidated net sales.
Summary of Long-lived Assets (Net) Attributable to Operations Geographical Segment	Long-lived assets (net) attributable to operations in the United States and foreign countries as of December 31, 2015 and 2014 were as follows: December 31, 2015 December 31, 2014 United States $ 17,451,598 $ - Foreign countries 12,081 - $ 17,463,679 $ -

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)Segmentshares
Accounting Policies [Abstract]
Cash frderally insured limit per bank		$ 250,000
Cash uninsured amount		$ 3,453,290
Percentage of valuation allowance	(34.00%)	(34.00%)
Warrants to purchase of common stock | shares		9,132,002
Accumulated deficit	$ 1,033,291	$ 8,569,841
Working capital deficit		$ 6,165,812
Number of operating segment | Segment		1

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Schedule of Assumptions Used for Fair Value of Warrant Derivative Liabilities (Details) - $ / shares	Nov. 12, 2015	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Stock Price	$ 0.46	$ 0.69
Exercise Price	$ 0.49	$ 0.74	$ 0.33
Expected Life (in years)	10 years		4 years 6 months
Stock Volatility	154.00%	15207.00%	125.00%
Risk-Free Rate	2.32%	2.27%	1.80%
Dividend Rate	0.00%	0.00%	0.00%
Outstanding Shares of Common Stock	4,547,243	81,692,954	62,100,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative)	Dec. 17, 2015USD ($)$ / sharesshares	Dec. 03, 2015	Nov. 15, 2015USD ($)shares	Nov. 15, 2015AUDshares	Aug. 18, 2015USD ($)$ / sharesshares	Jun. 26, 2015USD ($)	Jan. 22, 2015USD ($)	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / shares	Nov. 12, 2015$ / shares
Aggregate purchase price of business								$ 250,000
Net inocme								(7,536,548)	$ (960,092)
Interest expense recorded								$ (958,740)
Number of shares contibuted | shares								400,000
Capital stock per share | $ / shares								$ 0.65
Warrant exercise price | $ / shares								$ 0.74	$ 0.33	$ 0.49
Knight Therapeutics Inc [Member]
Aggregate purchase price of business						$ 1,200,000
Present value of future payments								$ 515,854
Interest expense recorded								37,372
Knight Therapeutics Inc [Member] | Security Agreement [Member]
Amortization expense								$ 70,655
Estimated useful lives of intangible property								5 years
Hand MD LLC [Member]
Number of shares contibuted | shares					2,142,857
Common stock percentage					50.00%
Capital stock per share | $ / shares					$ 0.70
Inventory purchase					$ 106,000
Present value of future royalty payments								$ 258,897
Hand MD LLC [Member] | License Agreement [Member]
Sales percentage					5.00%
Percentage of amount recevied from sublicensess					5.00%
Hand MD LLC [Member] | License Agreement [Member] | Second Year [Member]
Present value of future royalty payments					$ 250,000
Hand MD LLC [Member] | License Agreement [Member] | Thired Year [Member]
Present value of future royalty payments					500,000
Hand MD LLC [Member] | Consulting Agreement [Member]
Amortization expense					$ 118,045
Estimated useful lives of intangible property					5 years
Consulting fee paid					$ 10,000
Breakthrough Products, Inc [Member] | Stock Purchase Agreement [Member]
Sales percentage					5.00%
Net sales					$ 5,000,000
Number of shares contibuted | shares					6,000,000
Breakthrough Products, Inc [Member] | Settlement Agreement [Member]
Estimated useful lives of intangible property	5 years
Number of shares contibuted | shares	3,000,000
Capital stock per share | $ / shares	$ 5
Warrant exercise price | $ / shares	$ 0.001
Breakthrough Products, Inc [Member] | Settlement Agreement [Member] | Non-compete Provision [Member]
Amortization expense	$ 4,583
Estimated useful lives of intangible property	3 years
TPR Investments Pty Ltd [Member] | Stock Purchase Agreement [Member]
Amortization expense			$ 28,333
Company's expected revenues								2,513,990
Net inocme								966,672
Estimated useful lives of intangible property			5 years	5 years
Number of shares contibuted | shares			3,571,428	3,571,428
TPR Investments Pty Ltd [Member] | Stock Purchase Agreement [Member] | AUD [Member]
Amount payable under the purchase agreement | AUD				AUD 3,500,000
Total payments of acquire assets | AUD				AUD 4,000,000
TPR Investments Pty Ltd [Member] | Stock Purchase Agreement [Member] | Non-compete Provision [Member]
Estimated useful lives of intangible property			5 years	5 years
Knight [Member]
Sales percentage		60.00%
Amortization expense								384,720
UrgentRx Sellers [Member] | Breakthrough Products, Inc [Member] | Settlement Agreement [Member]
Company's expected revenues	$ 90,590
Net inocme	$ 80,249
Focus Factor Business [Member]
Aggregate purchase price of business							$ 6,000,000
Amount payable under the purchase agreement							4,500,000
Company's expected revenues								10,482,367
Net inocme								$ 1,216,928
Focus Factor Business [Member] | January 20, 2016 [Member]
Amount payable under the purchase agreement							750,000
Focus Factor Business [Member] | January 20, 2017 [Member]
Amount payable under the purchase agreement							$ 750,000

Acquisitions - Purchase Price A

Acquisitions - Purchase Price Allocation Assets Acquired and Liabilities Assumed on Estimated Fair Values (Details)	Dec. 31, 2015USD ($)
Factor Nutrition Labs, LLC [Member]
Accounts Receivable	$ 2,733,167
Inventory	67,113
Intellectual Property	$ 1,000,000
License agreement
Non-compete provision	$ 50,000
Non-solicitation provision	50,000
Intangible assets-Customer relationships	1,941,030
Goodwill	2,071,517
Accounts Payable	$ (971,381)
Royalty payable
Accrued Expenses	$ (941,446)
Others
Total Liabilities	$ 6,000,000
Knight Therapeutics Inc [Member]
Accounts Receivable	58,054
Inventory	204,925
Intellectual Property	100,000
License agreement	$ 606,553
Non-compete provision
Non-solicitation provision
Intangible assets-Customer relationships
Goodwill
Accounts Payable	$ (51,795)
Royalty payable
Accrued Expenses	$ (148,520)
Others
Total Liabilities	$ 769,217
Hand MD LLC [Member]
Accounts Receivable
Inventory
Intellectual Property	$ 100,000
License agreement	$ 1,670,675
Non-compete provision
Non-solicitation provision
Intangible assets-Customer relationships
Goodwill
Accounts Payable
Royalty payable	$ (258,897)
Accrued Expenses
Others	$ (11,778)
Total Liabilities	1,500,000
Breakthrough Products, Inc [Member]
Cash	2,298,619
Accounts Receivable	(68,976)
Inventory	234,709
Prepaid expenses	57,569
Intellectual Property	$ 100,000
License agreement
Non-compete provision	$ 50,000
Non-solicitation provision
Intangible assets-Customer relationships
Goodwill	$ 3,253,160
Accounts Payable	$ (741,822)
Royalty payable
Accrued Expenses	$ (2,202,848)
Others
Total Liabilities	$ 2,980,411
TPR Investments Pty Ltd [Member]
Cash	1,584,642
Accounts Receivable	30,684
Inventory	134,212
Prepaid expenses	141,070
Fixed Assets, net	5,698
Intangible assets, Net	3,493
Blogger Database	200,000
Customer Database	500,000
Intellectual Property	$ 100,000
License agreement
Non-compete provision	$ 50,000
Non-solicitation provision
Intangible assets-Customer relationships
Goodwill	$ 6,174,899
Accounts Payable	$ (77,064)
Royalty payable
Accrued Expenses	$ (56,224)
Dividends Payable	(1,177,152)
Provision for Income Tax	$ (518,558)
Others
Total Liabilities	$ 7,095,700

Acquisitions - Purchase Price46

Acquisitions - Purchase Price Allocated to Acquisition of Assets (Details)	Dec. 31, 2015USD ($)
Factor Nutrition Labs, LLC [Member]
Total assets acquired	$ 6,000,000
Factor Nutrition Labs, LLC [Member] | January 22, 2015 [Member]
Cash payment	4,500,000
Factor Nutrition Labs, LLC [Member] | January 20, 2016 [Member]
Cash payment	750,000
Factor Nutrition Labs, LLC [Member] | January 20, 2017 [Member]
Cash payment	750,000
Breakthrough Products, Inc [Member] | UrgentRx [Member]
Stock payment	2,550,000
Stock warrants issued	430,411
Total assets acquired	2,980,411
TPR Investments Pty Ltd [Member] | Nomad Choice [Member]
Cash payment	2,848,800
Stock issued	1,750,000
Earn-out payment	2,496,900
Total assets acquired	$ 7,095,700

Acquisitions - Pro forma Result

Acquisitions - Pro forma Results of Acquisition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Breakthrough Products, Inc [Member]
Revenue	$ 2,722,288
Net income (loss)	(10,621,330)
TPR Investments Pty Ltd [Member]
Revenue	2,494,812
Net income (loss)	(909,280)
Focus Factor Business [Member]
Revenue	12,695,295	$ 10,629,171
Net income (loss)	$ (183,471)	$ 932,209

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Provision for income taxes		$ 389,945
Percentage of deferred tax asset	0.00%	5.80%
Breakthrough Products, Inc [Member]
Valuation allowance percentage		100.00%
Net operating loss carryforwards		$ 25,137,583
Breakthrough Products, Inc [Member] | US Tax Authority [Member]
Valuation allowance percentage		100.00%
Net operating loss carryforwards		$ 33,707,458

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. Statutory Rate	34.00%	34.00%
U.S. effective rate in excess of AU rate	0.00%	1.00%
U.S. valuation allowance	(34.00%)	(34.00%)
Foreign Tax - Australia	0.00%	6.80%
Total provision for income taxes	0.00%	5.80%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Deferred tax assets	$ 11,460,536	$ 241,245
Valuation allowance for deferred tax assets	$ (11,460,536)	$ (241,245)
Net deferred tax assets

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Bad debt expense	$ (121,291)

Accounts Receivable - Accounts

Accounts Receivable - Accounts Receivable, Net of Allowances (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Trade accounts receivable	$ 4,101,148	$ 2,898
Less allowances	(121,291)
Total accounts receivable, net	$ 3,979,857	$ 2,898

Prepaid Expenses - Summary of P

Prepaid Expenses - Summary of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expense and Other Assets [Abstract]
Advances for inventory	$ 171,494
Media production	55,849
Insurance	54,519	$ 10,000
Trade shows	45,700
Deposits	41,228
Consultants	24,000
Rent	16,216
Miscellaneous	13,428
Total	$ 422,434	$ 10,000

Concentration of Credit Risk (D

Concentration of Credit Risk (Details Narrative)	12 Months Ended
	Dec. 31, 2015USD ($)Customer
Cash frderally insured limit per bank | $	$ 250,000
Cash uninsured amount | $	$ 3,453,290
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration risk percentage	78.00%
Number of customer accounted for accounts receivable | Customer	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration risk percentage	71.00%
Number of customer accounted for accounts receivable | Customer	2

Concentration of Credit Risk -

Concentration of Credit Risk - Summary of Major Suppliers (Details)	12 Months Ended
	Dec. 31, 2015
Suppliers One [Member]
Name of the Product	FOCUSfactor
Address of the suppliers	Pittsburgh, PA
City of suppliers	Tustin, CA
Suppliers Two [Member]
Name of the Product	Flat Tummy Tea
Address of the suppliers	Highland, NY
City of suppliers	-
Suppliers Three [Member]
Name of the Product	Neuragen
Address of the suppliers	Linthicum Heights, MD
City of suppliers	-
Suppliers Four [Member]
Name of the Product	UrgentRx
Address of the suppliers	Ogden, UT
City of suppliers	-

Inventory - Schedule of Carryin

Inventory - Schedule of Carrying Value of Inventory (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 535,908
Components	115,340
Raw Materials	$ 35,406
Energy product		$ 26,064
Total inventory	$ 686,655	$ 26,064

Fixed Assets and Intangible A57

Fixed Assets and Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Assets
Depreciation expenes	$ 1,513	$ 0
Amortization expense	$ 606,489	$ 0

Fixed Assets and Intangible A58

Fixed Assets and Intangible Assets - Summary of Fixed and Intangible Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Assets
Property and equipment	$ 18,187
Less accumulated depreciation	(6,170)
Fixed assets, net	12,017
FOCUSfactor intellectual property	1,000,000
Intangible assets subject to amortization	5,521,751
Less accumulated amortization	(606,489)
Intangible assets, net	$ 5,915,262

Fixed Assets and Intangible A59

Fixed Assets and Intangible Assets - Summary of Estimated Aggregate Amortization Expense (Details)	Dec. 31, 2015USD ($)
Assets
2,016	$ 1,111,229
2,017	1,111,229
2,018	1,109,070
2,019	1,094,329
2,020	$ 489,405

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Apr. 02, 2014	Apr. 02, 2014	Oct. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Nov. 12, 2015
Proceeds from promissory note				$ 11,500,000	$ 100,000
Promissory note converted into number of shares				400,000
Accrued consulting fees per month				$ 180,000
Bonus paid				486,958
Outstanding balance of consulting fees				0
Due from related party					16,077
Due to related party				3,162,060	100,000
Payroll expense				$ 128,237	$ 10,867
Hand MD LLC [Member]
Percentage of ownership interest				50.00%
Payroll expense				$ 40,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member]
Amount owed to related party				4,267,268		$ 3,571,314
Knight Therapeutics Inc [Member] | Security Agreement [Member]
Amount owed to related party				925,000
Knight Therapeutics Inc [Member] | Royalty Distribution Agreement [Member]
Amount owed to related party				71,573
Mr. Jack Ross [Member]
Options Outstanding, Granted	1,000,000	1,000,000
Value of granted options	$ 282,000
Proceeds from promissory note			$ 100,000
Debt instruments interest rate			10.00%
Debt instruments maturity date			Oct. 31, 2015
Accrued consulting fees per month				15,000
Ms. Harshbarger [Member] | Consulting Agreement [Member]
Due to related party				$ 10,000

Accounts Payable and Accrued 61

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Payroll	$ 128,237	$ 10,867
Legal fees	38,752	$ 10,867
Manufacturers	1,527,333
Promotions	1,213,021
Returns allowance	1,128,133
Customers	411,033
Interest	110,754
Royalties	71,573
Warehousing	31,748
Other	371,518	$ 15,859
Accounts payable and accrued liabilities	$ 5,032,102	$ 74,642

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Nov. 12, 2015	Jun. 26, 2015	Jan. 22, 2015	Dec. 31, 2015	Dec. 31, 2014
Amount of loan obligation				$ 9,870,170
Common stock price per share				$ 0.65
Amortization of debt discount	$ 2,067,258			$ 5,499,640
Unamortized debt discount				(2,536,419)
Interest expense paid				(958,740)
Note payable				750,000
Fair value of derivative liability	2,067,258			$ 3,096,179
StWarrant [Member]
Common stock price per share				$ 1
Loan Agreement [Member]
Common stock price per share				$ 1
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member]
Debt instrument interest rate percentage			0.00%
Note issued as part of asset purchase agreement			$ 1,500,000
Note maturity date			Jan. 20, 2017
Note payable				$ 1,500,000
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2016 [Member]
Note payable			$ 750,000
Asset Purchase Agreement [Member] | January 22, 2015 Loan Two [Member] | January 20, 2017 [Member]
Note payable			750,000
Security Agreement [Member]
Recognized amortization of deferred financing costs				925,000
Security Agreement [Member] | June 26, 2015 Security Agreement [Member]
Deferred financing costs				10,486
Recognized amortization of deferred financing costs				2,643
Security Agreement [Member] | June 26, 2015 Security Agreement [Member] | U.S [Member]
Percentage of sale revenue net		5.00%
Security Agreement [Member] | June 26, 2015 Security Agreement [Member] | Quarter Ending September 30, 2015 [Member]
Note payable		$ 250,000
Security Agreement [Member] | June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member]
Note payable		700,000
Security Agreement [Member] | June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member] | Minimum [Member]
Note payable		$ 12,500
Knight Therapeutics Inc [Member] | Loan Agreement [Member]
Loan amount	5,500,000		6,000,000
Expences associated with loan	$ 24,000		$ 40,000
Debt instrument interest rate percentage	15.00%		15.00%
Convertible equity offering			$ 1,000,000
Change in loan interest rate	13.00%		13.00%
Revenue			$ 13,000,000
Net income (loss)			$ 2,000,000
Amount of loan obligation				4,875,000
Number of warrants to purchase common stock	5,550,625
Common stock price per share	$ 0.49
Percentage of shares purchaseable under warrants	6.50%
Deferred financing costs				289,045
Recognized amortization of deferred financing costs				136,207
Interest expense paid				805,686
Accrued interest expense				0
Note maturity date	Nov. 11, 2017
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Maximum [Member]
Number of warrants to purchase common stock	4,547,243
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | StWarrant [Member]
Number of warrants to purchase common stock			4,595,187
Warrants exercise price			$ 1
Beneficial conversion feature of warrants			$ 1,952,953
Amortization of debt discount				1,952,953
Unamortized debt discount				607,732
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | LT Warrant [Member]
Number of warrants to purchase common stock			3,584,759
Warrants exercise price			$ 0.34
Common stock price per share			$ 1
Percentage of shares purchaseable under warrants			25.00%
Beneficial conversion feature of warrants			$ 1,462,560
Amortization of debt discount				854,828
Unamortized debt discount				$ 607,732
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | January 22, 2015 Loan One [Member]
Debt instrument interest rate percentage			5.00%
Amount of loan obligation			$ 300,000
Aggregate consideration to be paid			100,000
Capital expenditures			100,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants [Member]
Beneficial conversion feature of warrants	$ 2,553,287
Number of warrants outstanding	5,550,625			5,550,625
Amortization of debt discount				$ 2,553,287
Unamortized debt discount				1,928,686
Deferred financing costs				233,847
Recognized amortization of deferred financing costs				15,675
Interest expense paid				110,753
Accrued interest expense				$ 110,753
Fair value of derivative liability	$ 4,547,243
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Knight Warrants One [Member]
Beneficial conversion feature of warrants	$ 2,067,258
Number of warrants outstanding	4,547,243			4,547,243
Amortization of debt discount				$ 138,571
Unamortized debt discount				1,928,686
Accrued interest expense				$ 5,500,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Origination Fee [Member]
Expences associated with loan	$ 110,000		120,000
Knight Therapeutics Inc [Member] | Loan Agreement [Member] | Work Fee [Member]
Expences associated with loan	$ 55,000		$ 60,000
Neuragen Corp [Member] | Security Agreement [Member] | June 26, 2015 Security Agreement [Member]
Debt instrument interest rate percentage		0.00%
Note issued as part of asset purchase agreement		$ 950,000
Total payments of acquire assets		$ 1,200,000
Neuragen Corp [Member] | Security Agreement [Member] | June 26, 2015 Security Agreement [Member] | U.S [Member]
Percentage of sale revenue net		2.00%

Notes Payable - Schedule of Loa

Notes Payable - Schedule of Loan Payable (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Loans payable	$ 12,406,589
Unamortized debt discount	(2,536,419)
Total	9,870,170
Less: Current portion	(3,912,060)
Long-term portion	$ 5,958,110

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Nov. 12, 2015
Common stock, shares authorized	300,000,000	75,000,000
Forward stock split	30 for 1 forward stock split
Common stock, shares issued	81,692,954	62,100,000
Common stock purchase price per share	$ 0.65
Common stock value	$ 817	$ 621
Common stock issued for cash shares	400,000
Number of shares cancelled		135,900,000
Pre-Stock Split shares		4,530,000
Value of stock held for future issuance	$ 28,000	$ 40,000
Common stock, shares outstanding	81,692,954	62,100,000	4,547,243
Accounts Payable [Member]
Common stock purchase price per share	$ 0.70
Common stock issued for cash shares	292,857
Note Holder [Member]
Common stock, shares issued	400,000
Common stock purchase price per share	$ 0.25
Common stock value	$ 100,000
Loan Agreement [Member]
Common stock, shares issued	5,550,625
Common stock purchase price per share	$ 1
Contribution Agreement [Member] | Hand Md Corp [Member]
Common stock, shares issued	2,142,857
Common stock purchase price per share	$ 0.70
Percentage of outstanding capital	50.00%
Stock Purchase Agreement [Member] | Nomad Choice [Member]
Common stock, shares issued	3,571,428
Common stock purchase price per share	$ 0.35
Percentage of outstanding capital	100.00%
Stock Purchase Agreement [Member] | Breakthrough Products, Inc [Member]
Common stock, shares issued	3,000,000
Common stock purchase price per share	$ 0.85
Percentage of outstanding capital	100.00%
Merger Agreement [Member]
Common stock, shares issued		16,000,000
Common stock value		$ 25,000
ST Warrant [Member]
Common stock, shares issued	4,595,187
Common stock purchase price per share	$ 1
Board of Directors [Member] | Minimum [Member]
Common stock, shares authorized	75,000,000
Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized	300,000,000
Investor [Member] | Stock Purchase Agreement [Member]
Common stock, shares issued	2,000,000
Common stock purchase price per share	$ 0.25
Common stock value	$ 500,000

Commitments and Contingencies65

Commitments and Contingencies (Details Narrative)	Dec. 08, 2014USD ($)	Apr. 30, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015AUD
Operating lease expiration date		Mar. 31, 2017
Rent expense		$ 8,923
Sublease rent		$ 3,010
Subsidiary [Member]
Rent expense	$ 894
November 2016 [Member]
Rent expense			$ 4,200
November 2016 [Member] | AUD [Member]
Rent expense | AUD				AUD 5,500
December 2016 [Member]
Rent expense			$ 5,500
December 2016 [Member] | AUD [Member]
Rent expense | AUD				AUD 5,500

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments For Operating Leases (Details)	Dec. 31, 2015USD ($)
2,016	$ 220,676
2,017	27,294
Total	247,970
Subsidiary [Member]
2,016	10,728
2,017	9,834
Total	$ 20,562

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	Dec. 14, 2015	Nov. 12, 2015	Apr. 02, 2014	Apr. 02, 2014	Dec. 31, 2015	Dec. 31, 2014	Jul. 30, 2014
Stock-based compensation expense					$ 523,714	$ 282,247
Estimated fair value of Company's common stock		$ 0.49			$ 0.74	$ 0.33
Risk-free interest rate		2.32%			2.27%	1.80%
Volatility rate		154.00%			15207.00%	125.00%
Expected lives		10 years				4 years 6 months
Dividend yield		0.00%			0.00%	0.00%
Stock options outstanding intrinsic value					$ 1,400,000
Mr. Jack Ross [Member]
Options Outstanding, Granted			1,000,000	1,000,000
Stock options exercise price per share				$ 0.25
Two Board Members [Member]
Options Outstanding, Granted	1,000,000
Stock options exercise price per share	$ 0.25
Two Employees Members [Member]
Options Outstanding, Granted	1,000,000
Stock options exercise price per share	$ 0.65
Equity Incentive Plan 2014 [Member]
Common stock shares reserved for issuance							15,525,000

Stock Options - Summary of Opti

Stock Options - Summary of Options Outstanding by Price Range (Details) - Stock Option Plan [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Options Outstanding, Number Outstanding | shares	5,000,000
Options Outstanding, Remaining Average Contractual Life	8 years 7 months 13 days
Options Outstanding, Weighted Average Exercise Price	$ 0.41
Options Exercisable, Number Exercisable | shares	3,000,000
Options Exercisable, Weighted Average Exercise Price	$ 0.25
Minimum [Member]
Options Outstanding, exercise price	0.25
Maximum [Member]
Options Outstanding, exercise price	$ 65

Stock Options - Summary of Stoc

Stock Options - Summary of Stock Options Activity (Details) - Stock Option Plan [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Options Outstanding, Outstanding at Beginning balance | shares	1,000,000
Options Outstanding, Granted | shares	4,000,000
Options Outstanding, Exercised | shares
Options Outstanding, Expired or canceled | shares
Options Outstanding, Outstanding at Ending balance | shares	5,000,000
Weighted Average Exercise Price, Outstanding at Beginning balance | $ / shares	$ 0.25
Weighted Average Exercise Price, Granted | $ / shares	$ 0.45
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Expired or canceled | $ / shares
Weighted Average Exercise Price, Outstanding at Ending balance | $ / shares	$ 0.41

Stock Warrants - Summary of War

Stock Warrants - Summary of Warrants Outstanding by Price Range (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Exercise Price Range One [Member]
Warrants Outstanding, exercise prices	$ 0.34
Warrants Outstanding, Number Outstanding | shares	3,584,759
Warrants Outstanding, Remaining Average Contractual Life	9 years 1 month 6 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.34
Warrants Exercisable, Number Exercisable | shares	3,584,759
Warrants Exercisable, Weighted Average Exercise Price	$ 0.34
Exercise Price Range Two [Member]
Warrants Outstanding, exercise prices	$ 0.49
Warrants Outstanding, Number Outstanding | shares	4,547,243
Warrants Outstanding, Remaining Average Contractual Life	9 years 10 months 24 days
Warrants Outstanding, Weighted Average Exercise Price	$ 0.49
Warrants Exercisable, Number Exercisable | shares	4,547,243
Warrants Exercisable, Weighted Average Exercise Price	$ 0.49
Exercise Price Range Three [Member]
Warrants Outstanding, exercise prices	$ 5
Warrants Outstanding, Number Outstanding | shares	1,000,000
Warrants Outstanding, Remaining Average Contractual Life	3 years
Warrants Outstanding, Weighted Average Exercise Price	$ 5
Warrants Exercisable, Number Exercisable | shares	1,000,000
Warrants Exercisable, Weighted Average Exercise Price	$ 5

Stock Warrants - Summary of Sto

Stock Warrants - Summary of Stock Warrants Activity (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Warrants Outstanding, Beginning balance | shares
Warrants, Granted | shares	19,277,814
Warrants, Exercised | shares	(10,145,812)
Warrants, Expired or canceled | shares
Warrants Outstanding, Ending balance | shares	9,132,002
Warrants Outstanding, Weighted Average Exercise Price, Beginning balance | $ / shares
Weighted Average Exercise Price, Granted | $ / shares	$ 0.44
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.0000
Weighted Average Exercise Price, Expired or canceled | $ / shares
Warrants Outstanding, Weighted Average Exercise Price, Ending balance | $ / shares	$ 0.92

Derivatives (Details Narrative)

Derivatives (Details Narrative) - USD ($)	Nov. 12, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair value of derivative liability	$ 2,067,258	$ 3,096,179
Amortization of debt discount	$ 2,067,258	5,499,640
Warrant [Member]
Fair value of derivative liability		$ 1,028,921

Derivatives - Schedule of Assum

Derivatives - Schedule of Assumptions Used For Fair Value of Derivative (Details)	Nov. 12, 2015	Dec. 31, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Risk-free interest rate	2.32%	2.27%	1.80%
Expected remaining term	10 years		4 years 6 months
Expected volatility	154.00%	15207.00%	125.00%
Dividend yield	0.00%	0.00%	0.00%

Segments - Summary of Net Sales

Segments - Summary of Net Sales Attributed to Customers Geographical Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 13,456,377	$ 9,158
United States [Member]
Revenue	13,129,753	$ 9,158
Foreign Countries [Member]
Revenue	$ 326,624

Segments - Summary of Net Sal75

Segments - Summary of Net Sales Attributed to Customers Product Group (Details) - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Revenue		$ 13,456,377	$ 9,158
Focus Factor Business [Member]
Revenue		10,482,367
Flat Tummy Tea [Member]
Revenue		2,513,990
Other [Member]
Revenue	[1]	$ 460,020	$ 9,158
[1]	Net sales for any other product group of similar products are less than 10% of consolidated net sales.

Segments - Summary of Net Sal76

Segments - Summary of Net Sales Attributed to Customers Product Group (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Other [Member] | Sales Revenue, Net [Member]
Concentration risk percentage	10.00%	10.00%

Segments - Summary of Long-live

Segments - Summary of Long-lived Assets (Net) Attributable to Operations Geographical Segment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Long-lived assets net	$ 17,423,679
United States [Member]
Long-lived assets net	17,411,598
Foreign Countries [Member]
Long-lived assets net	$ 12,081